Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $3 | $3 | $3 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.2% | 3.6% | -0.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.9% | 79.6% | 87.3% | 84.7% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 54.2% | 53.7% | 51.5% | 51% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 35.6% | 35.6% | 40.1% | 39.4% |
| EPS Diluted | 0.42 | 0.41 | 0.45 | 0.44 |
| % Growth | 2.4% | -8.9% | 2.3% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |